Sutro Biopharma (STRO) Corporate presentation summary

Platform innovation and technology

• Proprietary platform enables site-specific conjugation using non-natural amino acids and click chemistry for uniform, stable ADCs.

• Versatile linker-payload combinations and scalable cell-free system support consistent quality from discovery to commercial scale.

• Platform optimizes antibody, linker, and payload to expand the therapeutic window, minimize toxicity, and maximize efficacy.

• Industry-leading ADC exposure achieved, driving improved safety and efficacy profiles in preclinical models.

Pipeline and clinical development

• Advancing single- and dual-payload ADCs targeting complex tumor antigens with limited competition.

• Three INDs planned in three years: STRO-004 (TF), STRO-006 (ITGB6), and STRO-227 (PTK7 dual-payload).

• Initial Phase 1 data for STRO-004 expected mid-2026; IND submissions for STRO-006 and STRO-227 anticipated in 2026.

• Well-capitalized with cash runway into at least Q2 2028.

Preclinical and clinical data highlights

• STRO-004 shows 50x preclinical exposure over approved TF ADC, with robust anti-tumor activity and reduced bleeding risk.

• STRO-006 demonstrates superior selectivity, safety, and anti-tumor activity in ITGB6+ models, outperforming competitors.

• STRO-227, a dual-payload ADC, exhibits broad anti-tumor activity and dose-dependent efficacy in multiple PDX models.

• Dual-payload ADCs overcome resistance and drive tumor regression in models resistant to single-payload ADCs.